Therapy of Acinetobacter baumannii: a systematic review
- Author:
Yin-Yin GUO
1
Author Information
1. Peking University Third Hospital
- Publication Type:Journal Article
- Keywords:
Acinetobacter baumannii;
Ampicillin/ subactam;
Cefoperazone/subactam;
Colistin;
Improvement;
Meta-analysis
- From:
Chinese Pharmaceutical Journal
2012;47(23):1956-1960
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To assess the efficacy and safety of different therapeutic regimens for Acinetobacter baumannii infection. METHODS: PUBMED (1995 to 2011), Cochrane Central Register of Controlled Trails (Issue 7, 2011), CNKI (1979 to 2011), and VIP (1989 to 2011) were searched for randomized controlled trial, quasi-randomized controlled trial, prospective and retrospective cohort study. A meta-analysis was performed with Cochrane Collaboration's RevMan 5.0 software. RESULTS: Eight literatures involving 544 patients with Acinetobacter baumannii infection were identified. Five studies used ampicillin/sulbactam. The analysis showed that there was statistically significant difference in the success rate between ampicillin/sulbactam and other drugs with OR of 1.69 and 95% CI of 1.03 to 2.75 and in mortality with OR of 0.51 and 95% CI of 0.29 to 0.89.As for improvement, bacteriologic success, treatment failure and adverse events, there was no statistically significant difference. There was one study involving cefoperazone/sulbactam and four studies on colistin. As far as bacteriologic success, clinical success and adverse events were concerned, there was no statistically significant difference. However, patients receiving colistin treatment had higher mortality with OR of 1.76 and 95% CI of 1.09 to 2.86. CONCLUSION: Ampicillin/sulbactam has better effect against Acinetobacter baumannii. It can improve the symptoms and clinical signs and dose not have significant adverse effect.
